Agharkar Institute Develops Biodegradable Nanocarrier for Dual Gene Silencing in Breast Cancer — Precision Nanomedicine

<h3>Overview</h3> <p>Scientists from the <strong>Agharkar Research Institute (ARI)</strong>, an autonomous institute under the <strong>Department of Science &amp; Technology (DST)</strong>, have created a biodegradable nanocarrier that can silence two major cancer‑survival genes in breast cancer. The platform uses <span class="key-term" data-definition="Application of nanotechnology for diagnosis, treatment or prevention of disease; relevant to GS3: Science &amp; Technology and health sector">nanomedicine</span> to deliver therapeutic RNA molecules directly to tumour cells, reducing systemic toxicity.</p> <h3>Key Developments</h3> <ul> <li>Construction of <span class="key-term" data-definition="Nanoparticles made of silica with pores of 2‑50 nm, offering high drug loading capacity; important for GS3: Emerging technologies">mesoporous silica nanoparticles</span> (MSNs) that are fully biodegradable.</li> <li>Functionalisation with a <span class="key-term" data-definition="Short nucleic‑acid molecule that binds specifically to the MUC1 protein overexpressed on many cancer cells, enabling targeted delivery; GS3: Biotechnology">MUC1 aptamer</span> and protamine biopolymer to achieve tumour‑specific uptake.</li> <li>Simultaneous loading of <span class="key-term" data-definition="Small interfering RNA, short double‑stranded RNA that can silence specific genes via RNA interference; GS3: Biotechnology">siRNA</span> against the anti‑apoptotic genes <strong>MCL‑1</strong> and <strong>Survivin</strong> – a <span class="key-term" data-definition="Simultaneous inhibition of two genes, here MCL‑1 and Survivin, to induce cancer cell death; GS3: Therapeutic strategies">dual gene silencing</span> approach.</li> <li>Glutathione‑responsive release mechanism that triggers payload delivery inside the tumour micro‑environment.</li> <li>In‑vivo validation in <span class="key-term" data-definition="Severe Combined Immunodeficiency mice lacking functional immune system, used for human tumour xenograft studies; GS3: Research models">SCID mice</span> showing high tumour accumulation and minimal systemic toxicity.</li> </ul> <h3>Important Facts</h3> <ul> <li>The nanocarrier achieved >70 % knock‑down of both <strong>MCL‑1</strong> and <strong>Survivin</strong> in MCF‑7 breast cancer cells, leading to marked apoptosis.</li> <li>In SCID mouse models, tumour growth was reduced by more than 60 % compared with untreated controls.</li> <li>Histological analysis revealed no significant damage to major organs, indicating good safety profile.</li> <li>The study is published in <strong>Advanced Healthcare Materials</strong> (2026) and is funded by the DST, reflecting government support for high‑impact biotech research.</li> </ul> <h3>UPSC Relevance</h3> <p>The development illustrates the intersection of <span class="key-term" data-definition="Application of nanotechnology for diagnosis, treatment or prevention of disease; relevant to GS3: Science &amp; Technology and health sector">nanomedicine</span> and gene‑silencing technologies, both listed under GS3 topics on biotechnology and health. It showcases how government‑funded research institutes like ARI translate basic science into potential clinical solutions, a point often examined in questions on science policy, public‑private partnership, and health‑care innovation.</p> <p>Understanding terms such as <span class="key-term" data-definition="Nanoparticles made of silica with pores of 2‑50 nm, offering high drug loading capacity; important for GS3: Emerging technologies">mesoporous silica nanoparticles</span> and <span class="key-term" data-definition="Small interfering RNA, short double‑stranded RNA that can silence specific genes via RNA interference; GS3: Biotechnology">siRNA</span> helps candidates answer questions on emerging therapeutic modalities and their regulatory implications.</p> <h3>Way Forward</h3> <p>Further work should focus on scaling up the nanocarrier production, conducting toxicology studies in larger animal models, and seeking clinical trial approval. Policy‑wise, the DST may consider creating dedicated funding streams for translational nanomedicine, encouraging collaborations between research institutes, biotech firms, and hospitals. Strengthening regulatory frameworks for nanotechnology‑based therapeutics will ensure safe and rapid deployment of such precision medicines in India.</p>